News

Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment driver for the shares. The oral selective oestrogen receptor degrader has been cleared by the US Food and Drug Administration in combination...

The new business is expected to focus on industries including technology, healthcare, consumer and financial institutions.

Price targets for Hikma Pharmaceuticals are currently clustered in the £1,870 to £2,100 range, which sits above the latest fair value estimate of £19.70. Analysts linking these higher targets to Hikma Pharmaceuticals point to confidence in execution and valuation, although they also flag sensitivity to assumptions that could work against the stock if conditions change. As you read on, you will see how to interpret this evolving narrative and what to watch as new research comes...

Hammerson sits at the centre of a fresh round of price target moves, with a central Fair Value estimate now at £3.94 compared with £3.78 previously. Recent research has pushed targets into a range of 395 GBp to 454 GBp as analysts update their views on how the company’s revenue profile and earnings power might justify higher or more cautious valuations. As you read on, you will see how to interpret these shifts and track the evolving Hammerson story in your own portfolio decisions. Analyst...

Citigroup stock has delivered a very strong 3 year return, yet current valuation checks suggest the shares may still trade at a discount to what some intrinsic value models imply. For investors, the puzzle is how to weigh that past performance against signals that both the Excess Returns model and market multiples point to undervaluation. Citigroup has returned 271.9% over the past 3 years, which puts extra focus on whether the current price still leaves room relative to underlying earning...

In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.

Anthropic could give Morgan Stanley (MS) and Goldman Sachs (GS) key roles in handling its market deb

The bank had previously expected cuts in October and December 2026 and January 2027, but a stronger-than-expected August jobs report changed its outlook

The delayed easing cycle could protect interest income while making consumer credit increasingly expensive.

Citigroup has officially abandoned its expectations for Federal Reserve interest rate cuts in 2026.

Commitments run from $1.25 billion down to $750 million depending on rank

NTRS' NII rises 11% y/y in Q2, with lower funding costs and balance-sheet trends supporting momentum as management lifts 2026 growth guidance.

Here is how Citigroup (C) and Federal Agricultural Mortgage (AGM) have performed compared to their sector so far this year.

One enormous credit line could reshape the AI IPO race

Investing.com -- Citi raised its global data center growth forecasts as hyperscale investment in high-performance computing and AI workloads accelerates, and named a list of stocks it expects to benefit across multiple sectors.

Citigroup (C) anticipates regulatory approval from Beijing for a wholly-owned brokerage business, po

Baidu, Inc. (NASDAQ:BIDU) may have a new near-term catalyst on the horizon, with Citi opening a 30-Day Upside Catalyst Watch on the stock. On September 2, analyst Alicia Yap reiterated a Buy rating and a $166.00 price target on Baidu, Inc. (NASDAQ:BIDU), according to a press release statement. The rating affirmation follows the firm’s 2026 […]

C ramps up buybacks and dividends as excess capital, stronger earnings and business simplification support aggressive returns.

In recent days, Citigroup Inc. has launched a series of senior unsecured callable notes across multiple maturities, including fixed, floating-rate, and zero-coupon issues, while also completing several smaller bond offerings and facing a £4.7 million fine for past Russian sanctions breaches at its London branch. At the same time, Citi is expanding its role in next-generation payments through live blockchain-based Swift transactions and participation in a planned global bank-backed USD...

Investing.com -- Citi has recommended a short position in the U.S. dollar against the Canadian dollar, betting that stretched interest-rate differentials between the two countries will reverse in favor of the loonie as upcoming economic data challenge expectations for U.S. monetary policy.

In the latest trading session, Citigroup (C) closed at $134.38, marking a +1.39% move from the previous day.

Goldman Sachs wants the Fed to hike again while Citi calls for three cuts starting in October, and the gap between those two forecasts could quietly drain hundreds of dollars a year from your savings account.

Financial stocks were advancing late Wednesday afternoon, with the NYSE Financial Index adding 1% an

Investing.com -- Goldman Sachs believes the largest U.S. banks are likely to moderate capital deployment as regulatory buffers rise for a third consecutive year and excess capital levels shrink.

Financial stocks were advancing Wednesday afternoon, with the NYSE Financial Index and the State Str

Supply constraints may be leaving more upside on table

Citigroup has outperformed the Financial sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

The institutions that crypto was built to destroy are now racing to control its most important financial primitive. What happens to the rebellion when the banks become the infrastructure?

Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail...

JPM's Kinexys is gaining traction as blockchain settlement speeds fund transfers and supports deeper client ties and Payments growth.